Reductions in Drug Prices Possible With Most Favored Nation Executive Order but Large Reductions Unrealistic: Q&A With Kathy Oubre, MS

In the first part of this Q&A, Kathy Oubre, MS, chief executive officer of the Pontchartrain Cancer Center, explained what the executive order signed by the president in May that aimed to bring "most favored nation" pricing to the US entails and whether his stated goal of reducing prescription drug prices in the US is realistic. Oubre also discusses how the US may see some benefit from the executive order if parts of it are implemented correctly.